Conversation with The Cancer LetterFree Monica Bertagnolli’s Cancer Plan makes the most of her two roles: NCI director and leader of the National Cancer Program April 14, 2023Vol.49 No.15By Paul Goldberg and Matthew Bin Han Ong
Trials & Tribulations San Antonio Breast Cancer Symposium 2022 tackled big obstacles, recommended solutions for breast cancer progress April 14, 2023Vol.49 No.15By Angela DeMichele, Rajarshi Sengupta and Carlos L. Arteaga
Guest Editorial Mifepristone and the Administrative Procedure Act: Perspective of a former FDA commissioner and NCI director April 14, 2023Vol.49 No.15By Norman E. "Ned" Sharpless
Conversation with The Cancer LetterJudiciary Bipartisan Policy Center’s Anand Parekh: Rulings on USPSTF, mifepristone are ideological threats to evidence-based care April 14, 2023Vol.49 No.15By Matthew Bin Han Ong
Pragmatica-Lung, a landmark pragmatic trial with registrational intent, starts enrollment April 14, 2023Vol.49 No.15By Jacquelyn Cobb
Conversation with The Cancer Letter Gary Schwartz talks about his vision for Case CCC, leaving New York, his illustrious father—and Isaac Asimov April 07, 2023Vol.49 No.14By Paul Goldberg
NCI NCI Director Bertagnolli designs Cancer Plan to trigger national conversation, transform cancer research and care April 07, 2023Vol.49 No.14By Matthew Bin Han Ong
“Historic” cisplatin shortage leaves oncologists guessing whether they will have enough to treat the next patient April 07, 2023Vol.49 No.14By Jacquelyn Cobb
Guest Editorial Leading a matrix cancer center: Extensive responsibility, modest influence, little authority April 07, 2023Vol.49 No.14By George J. Weiner
